- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04008186
A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
February 1, 2024 updated by: Reata, a wholly owned subsidiary of Biogen
A Phase 1, Open-Label, 4-Part, Drug-Drug Interaction Study With Omaveloxolone in Healthy Subjects
This study will assess the potential for clinical drug-drug interactions between omaveloxolone and a number of substrates and inhibitors of metabolic enzymes and drug transporters.
Study Overview
Status
Completed
Conditions
Detailed Description
Study Sponsor, originally Reata Pharmaceuticals, Inc., is now Reata Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen.
Study Type
Interventional
Enrollment (Actual)
61
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75247
- Covance Clinical Research Unit (CRU) Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 53 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
Subjects must satisfy all of the following criteria at the Screening Visit unless otherwise stated:
- Males or females, of any race, between 18 and 55 years of age, inclusive.
- Body mass index between 18.0 and 32.0 kg/m2, inclusive, and a total body weight >50 kg.
- In good health.
- Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception.
- Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
Exclusion Criteria:
Subjects will be excluded from the study if they satisfy any of the following criteria at the Screening visit, unless otherwise stated:
- Significant history or clinical manifestation of any major system disorder, as determined by the investigator (or designee).
- History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator (or designee).
- History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (cholecystectomy will not be allowed; uncomplicated appendectomy and hernia repair will be allowed).
- History of alcoholism or drug/chemical abuse within 2 years prior to Check in (Day 1).
- Abnormal laboratory values considered clinically significant by the investigator
- Clinically significant abnormal 12 lead ECGs
- Personal history of unexplained syncopal events, or family history of long QT syndrome or sudden unexplained death in a young person.
- Pulse rate <50 bpm or systolic blood pressure <110 mmHg.
- Alcohol consumption of >21 units per week for males and >14 units for females.
- Positive urine drug screen or positive alcohol breath test result or positive urine drug screen.
- Positive hepatitis panel and/or positive human immunodeficiency virus test. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days prior to dosing or 5 half lives (if known), whichever is longer, prior to dosing.
- Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing, unless deemed acceptable by the investigator (or designee).
- Have previously completed or withdrawn from this study or any other study investigating omaveloxolone, and have previously received the investigational product.
- Subjects who, in the opinion of the investigator (or designee), should not participate in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Omaveloxolone and Multiple Drugs (Part 1)
Single oral doses of 2 mg midazolam, 1 mg repaglinide, 500 mg metformin, and a 10 mg rosuvastatin/0.25 mg digoxin cocktail on Days 1, 2, 3, and 5, respectively, and 18, 19, 20, and 22, respectively.
Oral doses of 150 mg omaveloxolone on Days 12 to 27
|
10 mg tablet
50 mg capsules
Other Names:
2 mg/mL oral solution
1 mg tablet
500 mg tablet
0.25 mg tablet
|
Experimental: Omaveloxolone & Gemfibrozil (Part 2)
Single oral doses of 150 mg omaveloxolone on Days 1 and 13.
Oral doses of 600 mg gemfibrozil (twice daily) on Days 10 to 18
|
50 mg capsules
Other Names:
600 mg tablet
|
Experimental: Omaveloxolone and Itraconazole (Part 3)
Single oral doses of 150 mg omaveloxolone on Days 1 and 13.
Oral doses of 200 mg itraconazole on Days 10 to 18.
|
50 mg capsules
Other Names:
100 mg capsule
|
Experimental: Omaveloxolone and Verapamil (Part 4)
Single oral doses of 150 mg omaveloxolone on Days 1 and 13.
Oral doses of 120 mg verapamil on Days 10 to 18.
|
50 mg capsules
Other Names:
120 mg tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 - Maximum concentration (Cmax) of probe drugs co-administered with omaveloxolone (midazolam, repaglinide, metformin, rosuvastatin, and digoxin)
Time Frame: 28 days
|
Pharmacokinetics will be assessed by blood sampling for midazolam, repaglinide, metformin, rosuvastatin, and digoxin to determine maximum observed concentration (Cmax).
|
28 days
|
Part 1 - Area under the plasma concentration-time curve of (AUC) for probe drugs co-administered with omaveloxolone (midazolam, repaglinide, metformin, rosuvastatin, and digoxin)
Time Frame: 28 days
|
Pharmacokinetics will be assessed by blood sampling for midazolam, repaglinide, metformin, rosuvastatin, and digoxin to determine area under the curve (AUC).
|
28 days
|
Part 2 - Maximum concentration (Cmax) of omaveloxolone
Time Frame: 23 days
|
Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine maximum observed concentration (Cmax).
|
23 days
|
Part 2 - Area under the omaveloxolone concentration-time curve (AUC)
Time Frame: 23 days
|
Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine area under the curve (AUC).
|
23 days
|
Part 3 - Maximum concentration (Cmax) of omaveloxolone
Time Frame: 23 days
|
Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine maximum observed concentration (Cmax).
|
23 days
|
Part 3 - Area under the omaveloxolone concentration-time curve (AUC)
Time Frame: 28 days
|
Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine area under the curve (AUC).
|
28 days
|
Part 4 - Maximum concentration (Cmax) of omaveloxolone
Time Frame: 23 days
|
Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine maximum observed concentration (Cmax).
|
23 days
|
Part 4 - Area under the omaveloxolone concentration-time curve (AUC)
Time Frame: 28 days
|
Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine area under the curve (AUC).
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Jennifer Zon, MD, Covance CRU Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 14, 2019
Primary Completion (Actual)
August 18, 2019
Study Completion (Actual)
August 28, 2019
Study Registration Dates
First Submitted
July 2, 2019
First Submitted That Met QC Criteria
July 2, 2019
First Posted (Actual)
July 5, 2019
Study Record Updates
Last Update Posted (Actual)
February 2, 2024
Last Update Submitted That Met QC Criteria
February 1, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Vasodilator Agents
- Anti-Infective Agents
- Central Nervous System Depressants
- Enzyme Inhibitors
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Antimetabolites
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protective Agents
- Cardiotonic Agents
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Calcium-Regulating Hormones and Agents
- Antifungal Agents
- Steroid Synthesis Inhibitors
- Calcium Channel Blockers
- 14-alpha Demethylase Inhibitors
- Cytochrome P-450 CYP2C8 Inhibitors
- Digoxin
- Midazolam
- Rosuvastatin Calcium
- Metformin
- Itraconazole
- Verapamil
- Gemfibrozil
- Repaglinide
Other Study ID Numbers
- 408-C-1806
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Adult Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
China Resources Biopharmaceutical Co., LtdPeking University Third HospitalRecruiting
-
Auzone Biological Technology Pty LtdCompleted
-
Mitsubishi Tanabe Pharma CorporationCompletedHealthy Adult SubjectsJapan
-
Alvotech Swiss AGIqvia Pty LtdCompletedHealthy Adult SubjectsNew Zealand, United Kingdom
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Connect Biopharma Australia Pty LtdCompletedHealthy Adult SubjectsAustralia
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHealthy Adult SubjectsChina
Clinical Trials on Rosuvastatin
-
AstraZenecaCompletedDyslipidemia | Kidney DiseaseUnited States, Puerto Rico
-
Yuhan CorporationCompletedHypertension | HyperlipidemiaKorea, Republic of
-
Ottawa Hospital Research InstituteUnknownVenous ThromboembolismCanada, Norway
-
Kobe UniversityCompletedCoronary Artery Disease Progression
-
National Institute of Diabetes and Digestive and...National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
Gachon University Gil Medical CenterDaewoong Pharmaceutical Co. LTD.UnknownCoronary Artery DiseaseKorea, Republic of
-
Alvogen KoreaCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedUnknownHealthyKorea, Republic of
-
Organon and CoCompleted